A Phase 1 Double-blinded, Randomized, Placebo-controlled Study for COVID-19 and Influenza Virus-Elicited Acute Respiratory Distress Syndrome (ARDS) Using Lomecel-B
Latest Information Update: 22 Feb 2024
At a glance
- Drugs Mesenchymal stem cell therapy-Longeveron (Primary)
- Indications COVID-19 respiratory infection; SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms RECOVER
- Sponsors Longeveron
- 16 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jun 2024.
- 02 Oct 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Jan 2024.
- 27 Apr 2023 Status changed from recruiting to active, no longer recruiting.